Users are using CBT to help with several conditions. It is generally mixed with CBD or other cannabinoids in hemp extracts to achieve entourage effects.
Currently, it is the most common minor cannabinoid used in the market. It has been demonstrated that it inhibits FAAH, raises AEA levels, and controls the cell cycle to boost the activity of the ECS.
The psychoactive delta-9-tetrahydrocannabinol (THC) and the nonpsychoactive cannabidiol (CBD) extracts from cannabis sativa have antitumor effects in various cancer models. These effects are conferred by the activation of CB-Rs that influence several signaling mechanisms, such as inhibiting cell proliferation and migration and inducing apoptosis.
Besides inhibiting tumor progression, plant-derived CBDs can alleviate neuropathic pain and nausea associated with cancer treatment. A recent study found that the synthetic cannabinoid JWH-133, a potent CB1-R agonist, decreased cancer cell invasiveness in a rat model with recurrent glioblastoma multiforme and improved the response to chemotherapy.
In addition, the cannabinoid AEA (cannabidiol acid) has demonstrated antitumoral properties in a mouse model with HER2-positive breast cancer and reduced metastasis to the brain and lungs. This effect was attributed to inhibiting the PI3K/Akt/mTOR and RSK signaling pathways and downregulating the expression of the breast cancer metastasis ID-1 enhancer. AEA also induces apoptosis and cell cycle arrest via the cAMP/protein kinase A and MAPK/ERK signaling pathways, which inhibit the proliferation of triple-negative MDA-MB-231 human breast cancer cells.
A CBT cannabinoid has been proven to slow the spread of various malignancies. In addition to its well-known psychotropic effects, cannabinoids also have a wide range of other medical properties. These include appetite stimulation, pain suppression, and the modulation of gastrointestinal motility. Furthermore, cannabinoids have been shown to prevent eye damage and lower intraocular pressure.
The visual CB1 receptors found in the ciliary epithelium, Schlemm’s canal, and the trabecular meshwork have been implicated in the reduction of IOP induced by cannabinoid treatment.
Insomnia is a common side effect of cancer treatment and survivorship. Between 30-50% of breast cancer survivors endorse clinically significant insomnia symptoms. Symptoms of insomnia in cancer patients negatively impact sleep, cognitive function, daytime functioning, and quality of life, increasing the risk of developing depression.
The proposed project aims to adapt and pilot-test a CBT-based insomnia intervention for adults who regularly use medical cannabis. Existing randomized efficacy trials have evaluated the effectiveness of sleep-focused interventions for individuals with comorbid insomnia and cannabis use disorder.
Scientists believe that CBT offers some beneficial effects when combined with other cannabinoids. For instance, it can inhibit THC’s psychoactive effect and prevent crystallization in CBD products. CBT can also strengthen the therapeutic effects of CBD and CBC. Moreover, it is likely to enhance the energy-boosting and focus-enhancing properties of CBG. It is also an excellent addition to hemp extract for people suffering from chronic pain due to rhododendron-related conditions. CBT is not anticipated to produce psychotropic effects because it does not bind to CB1 receptors. As a result, it is not listed as a prohibited substance and is consequently acceptable for use and possession. It is in hemp supplements containing cannabinoids like CBC, CBD, and others. Additionally, it is available in capsule form, which can be used orally. They provide a practical alternative for those who prefer not to taste their hemp products or dislike the complexity of tinctures.